Digital cognitive assessments and blood-based biomarkers in Alzheimer’s research
Cambridge Cognition
The spoken revolution in rater training assessment
Optimising outcome measures in cognitive drug trials for schizophrenia
The value of CNS-specific eCOA provider in clinical trials
Safety first: Cognition as a primary safety endpoint provides a competitive advantage
How to identify and remove CNS assessment errors to avoid jeopardising a trial
